Uptake of Sanofi's rights buyback indicates investors haven't written off Lemtrada…yet
This article was originally published in Scrip
A short while back, Sanofi invited the holders of the contingent value rights (CVRs) it issued when it bought Genzyme to let it know the minimum price they would accept for those rights, if it were to pay $1.50-1.75 per CVR (representing a premium of 7-25% on the then market value of those CVRs).
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.